NEW YORK, Oct. 16, 2017 (GLOBE NEWSWIRE) — Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced today that data from several of the Company’s development programs will be presented in oral sessions at the 30th Annual Congress of the European Association of Nuclear Medicine (EANM), which is being held in Vienna, Austria from October 21 through 25, 2017.